肺腺癌中缺氧诱导因子-1α调控程序性死亡因子配体1的表达
Role of hypoxia-inducible factor-1α in the regulation of programmed death ligand 1 expression in lung adenocarcinoma

DOI: 10.6040/j.issn.1671-7554.0.2016.1467

Keywords: 程序性死亡因子配体1,肺腺癌,缺氧诱导因子-1α,
Hypoxia-inducible factor-1α,Programmed death ligand 1,Lung adenocarcinoma

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion[J]. Nat Med, 2002, 8(8): 793-800.
[2]	Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639.
[3]	Chen TC, Wu CT, Wang CP, et al. Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof[J]. Oral Oncol, 2015, 51(11): 1004-1010.
[4]	Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis[J]. Cell Death Differ, 2008, 15(4): 678-685.
[5]	Rankin EB, Giaccia AJ. Hypoxic control of metastasis[J]. Science, 2016, 352(6282): 175-180.
[6]	Barsoum IB, Smallwood CA, Siemens DR, et al. A mechanism of hypoxia-mediated escape from adaptive immunity in cancer cells[J]. Cancer Res, 2014, 74(3): 665-674.
[7]	Noman MZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation[J]. J Exp Med, 2014, 211(5): 781-790.
[8]	Kishimoto K, Yoshida S, Ibaragi S, et al. Hypoxia-induced up-regulation of angiogenin, besides VEGF, is related to progression of oral cancer[J]. Oral Oncol, 2012, 48(11): 1120-1127.
[9]	Zheng YW, Li RM, Zhang XW, et al. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome[J]. Cancer Invest, 2013, 31(3): 197-205.
[10]	Lortet-Tieulent J, Soerjomataram I, Ferlay J, et al. International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women[J]. Lung Cancer, 2014, 84(1): 13-22.
[11]	Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135.
[12]	Shien K, Papadimitrakopoulou VA, Wistuba II. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer[J]. Lung Cancer, 2016, 99(2016): 79-87.
[13]	Sacher AG, Gandhi L. Biomarkers for the clinical use of PD-1/PD-L1 inhibitors in non-small-cell lung cancer: a review[J]. JAMA Oncol, 2016, 2(9): 1217-1222.
[14]	Bally AP, Austin JW, Boss JM. Genetic and epigenetic regulation of PD-1 expression[J]. J Immunol, 2016, 196(6): 2431-2437.
[15]	Semenza GL. Oxygen sensing, homeostasis, and disease[J]. N Engl J Med, 2011, 365(6): 537-547.
[16]	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(21): 2018-2028.
[17]	Groome PA, Bolejack V, Crowley JJ, et al. The IASLC lung cancer staging project: validation of the proposals for revision of the T, N, and M descriptors and consequent stage groupings in the forthcoming(seventh)edition of the TNM classification of malignant tumors[J]. J Thorac Oncol, 2007, 2(8): 694-705.
[18]	Urano N, Fujiwara Y, Doki Y, et al. Overexpression of hypoxia-inducible factor-1 alpha in gastric adenocarcinoma[J]. Gastric Cancer, 2006, 9(1): 44-49.
[19]	Liu SY, Chang LC, Pan LF, et al. Clinicopathologic significance of tumor cell-lined vessel and microenvironment in oral squamous cell carcinoma[J]. Oral Oncol, 2008, 44(3): 277-285.
[20]	Chang YL, Yang CY, Lin MW, et al. High co-expression of PD-L1 and HIF-1α correlates with tumor necrosis in pulmonary pleomorphic carcinoma[J]. Eur J Cancer, 2016, 60:125-135.
[21]	Miyake K, Yoshizumi T, Imura S, et al. Expression of hypoxia-inducible factor-1alpha, histone deacetylase 1, and metastasis-associated protein 1 in pancreatic carcinoma: correlation with poor prognosis with possible regulation[J]. Pancreas, 2008, 36(3): 1-9.
[22]	Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer[J]. Endocr Relat Cancer, 2006, 13(3): 739-749.
[23]	Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy[J]. Acta Pharm Sin B, 2015, 5(5): 378-389.
[24]	Palazon A, Goldrath AW, Nizet V, et al. HIF transcription factors, inflammation, and immunity[J]. Immunity, 2014, 41(4): 518-528.
[25]	刘金峰, 张楠, 徐超, 等. HIF-1α与HGF在非小细胞肺癌中的共表达及其与淋巴管生成的关系[J]. 山东大学学报(医学版), 2011, 49(11): 112-116. LIU Jinfeng, ZHANG Nan, XU Chao, et al. Co-expression of hypoxia-inducible factor-1α and hepatocyte growth factor in non-small-cell lung cancer and their association with lymphangiogenesis[J]. Journal of Shandong University(Health Sciences), 2011, 49(11): 112-116.
[26]	张浩, 任秀红, 刘莉. PD-L1和EGFR在非小细胞肺癌组织中的表达及相关性分析[J]. 疑难病杂志, 2015, 14(8): 786-792. ZHANG Hao, REN Xiuhong, LIU Li. Expression of PD-L1 and EGFR in non-small cell lung cancer and its clinical relationships[J]. Chin J Diffic and Compl Cas, 2015, 14(8): 786-792.
[27]	Ruf M, Moch H, Schraml P. PD-L1 expression is regulated by hypoxia inducible factor in clear cell renal cell carcinoma[J]. Int J Cancer, 2016, 139(2): 396-403.
[28]	Koh J, Jang JY, Keam B, et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor(HIF)-1α and STAT3[J]. Oncoimmunology, 2015, 5(3): e1108514.

Full-Text